Hervé Hoppenot

Chairman, President & CEO
Incyte Corporation

Hervé Hoppenot joined Incyte Corporation in 2014 as president and chief executive officer and was appointed chairman of the board of directors in 2015.

Prior to joining Incyte, Hoppenot was the president of Novartis Oncology, where he was responsible for translational medicine, development, approval and commercialization, which included $11 billion in global sales, the largest oncology pipeline in the industry, and 8,000 employees in 50 countries. Hoppenot joined Novartis in 2003 and in addition to his role as president, served as chief commercial officer, head of global product strategy & scientific development and senior vice president, head of global marketing. He started his career in 1983 with Rhone Poulenc, later known as Aventis, where he served in several senior roles of increasing responsibility, including vice president of oncology and head of the U.S. oncology business unit.

Hoppenot holds a diploma from ESSEC Business School.